AN2 Therapeutics (ANTX) Equity Average (2021 - 2026)

AN2 Therapeutics (ANTX) has 6 years of Equity Average data on file, last reported at $67.4 million in Q1 2026.

• Equity Average for Q1 2026 came in at $67.4 million, down 13.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $67.4 million (down 13.12% YoY), and the FY2025 annual result was $67.5 million, down 34.68% from the prior year.
• Equity Average climbed to $67.4 million in Q1 2026 per ANTX's latest filing, from $56.7 million in the prior quarter.
• Over five years, Equity Average peaked at $131.8 million in Q4 2023 and troughed at $34.0 million in Q1 2022.
• A 5-year average of $89.3 million and a median of $88.9 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2022 and 2024: Equity Average surged 536.73% in 2022, then sank 35.71% in 2024.
• A 5-year view of Equity Average shows it stood at $100.5 million in 2022, then surged by 31.22% to $131.8 million in 2023, then slumped by 35.71% to $84.8 million in 2024, then plunged by 33.08% to $56.7 million in 2025, then gained by 18.85% to $67.4 million in 2026.
• Business Quant data shows ANTX's Equity Average at $67.4 million in Q1 2026, $56.7 million in Q4 2025, and $64.6 million in Q3 2025.